NO20006452L - Inhibitors of NF-κB transcription factor - Google Patents

Inhibitors of NF-κB transcription factor

Info

Publication number
NO20006452L
NO20006452L NO20006452A NO20006452A NO20006452L NO 20006452 L NO20006452 L NO 20006452L NO 20006452 A NO20006452 A NO 20006452A NO 20006452 A NO20006452 A NO 20006452A NO 20006452 L NO20006452 L NO 20006452L
Authority
NO
Norway
Prior art keywords
disease
inhibitors
dermatosis
transcription factor
methods
Prior art date
Application number
NO20006452A
Other languages
Norwegian (no)
Other versions
NO20006452D0 (en
Inventor
James Francis Callahan
Marie C Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20006452D0 publication Critical patent/NO20006452D0/en
Publication of NO20006452L publication Critical patent/NO20006452L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)

Abstract

Det beskrives amino-indanon-inhibitorer av transkripsjonsfaktor NF-KB og farmasøytisk akseptable salter, hydrater og solvater derav, farmasøytiske prepara- ter av slike forbindelser, samt fremgangsmåter for behandling av sykdommer hvor aktivering av NF-tcB er implisert. Mer spesifikt beskrives fremgangsmåter for be- handling av en rekke sykdommer som er assosiert med NF-icB-aktivering, inklusi- ve inflammatoriske lidelser; spesielt reumatoid artritt; inflammatorisk tarmsykdom og astma; dermatose, inklusive psoriasis og akutt dermatose; autoimmune syk- dommer, vevs- og organavstøtning; Alzheimers sykdom; slag, aterosklerose; restenose; kreft, inklusive Hodgkins sykdom; og visse virusinfeksjoner, inklusive AIDS; osteoartritt; osteoporose; og Ataxia Telangiestasia, ved å administrere til en pasient som trenger det, en forbindelse i henhold til oppfinnelsen.There are disclosed amino-indanone inhibitors of transcription factor NF-κB and pharmaceutically acceptable salts, hydrates and solvates thereof, pharmaceutical preparations of such compounds, and methods of treating diseases in which activation of NF-tcB is implicated. More specifically, methods are described for treating a variety of diseases associated with NF-icB activation, including inflammatory disorders; especially rheumatoid arthritis; inflammatory bowel disease and asthma; dermatosis, including psoriasis and acute dermatosis; autoimmune diseases, tissue and organ rejection; Alzheimer's disease; stroke, atherosclerosis; restenosis; cancer, including Hodgkin's disease; and certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia, by administering to a patient in need thereof, a compound of the invention.

NO20006452A 1998-06-19 2000-12-18 Inhibitors of NF-κB transcription factor NO20006452L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19
PCT/US1999/013897 WO1999065495A1 (en) 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (2)

Publication Number Publication Date
NO20006452D0 NO20006452D0 (en) 2000-12-18
NO20006452L true NO20006452L (en) 2001-02-16

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006452A NO20006452L (en) 1998-06-19 2000-12-18 Inhibitors of NF-κB transcription factor

Country Status (17)

Country Link
EP (1) EP1085872A4 (en)
JP (1) JP2002518333A (en)
KR (1) KR20010052990A (en)
CN (1) CN1306428A (en)
AR (1) AR019871A1 (en)
AU (1) AU4699699A (en)
BR (1) BR9911151A (en)
CA (1) CA2335293A1 (en)
CO (1) CO5080752A1 (en)
CZ (1) CZ20004760A3 (en)
HU (1) HUP0102492A2 (en)
IL (1) IL140324A0 (en)
NO (1) NO20006452L (en)
PL (1) PL345577A1 (en)
TR (1) TR200003779T2 (en)
WO (1) WO1999065495A1 (en)
ZA (1) ZA200007448B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740107D1 (en) 1996-12-23 2011-03-10 Immunex Corp RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
EP1250137B1 (en) * 2000-01-24 2007-08-15 Genzyme Corporation Jak/stat pathway inhibitors and the use thereof for the treatment of primary generalized osteoarthritis
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1989203A2 (en) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
CA2769038A1 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Antiangiogenic small molecules and methods of use
US10160705B2 (en) 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en) 2012-10-31 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
PL345577A1 (en) 2001-12-17
AR019871A1 (en) 2002-03-20
ZA200007448B (en) 2001-12-12
AU4699699A (en) 2000-01-05
TR200003779T2 (en) 2001-06-21
BR9911151A (en) 2001-03-06
CZ20004760A3 (en) 2001-08-15
JP2002518333A (en) 2002-06-25
WO1999065495A1 (en) 1999-12-23
CN1306428A (en) 2001-08-01
CA2335293A1 (en) 1999-12-23
EP1085872A4 (en) 2003-04-16
IL140324A0 (en) 2002-02-10
HUP0102492A2 (en) 2001-11-28
EP1085872A1 (en) 2001-03-28
NO20006452D0 (en) 2000-12-18
KR20010052990A (en) 2001-06-25
CO5080752A1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
NO20006451L (en) Inhibitors of NF-κB transcription factor
NO20006452L (en) Inhibitors of NF-κB transcription factor
MY138352A (en) Benzothiazole derivatives
NO20045434L (en) A combination of an NMDA antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
GB0121033D0 (en) Organic compounds
MXPA04003439A (en) 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists.
FR2807431B1 (en) NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TW200505449A (en) Pharmaceutical compositions and dosage forms of thalidomide
GB0220187D0 (en) Organic compounds
DE60214198D1 (en) ISOXAZOLYL-PYRIMIDINES AS INHIBITORS OF SRC AND LCK PROTEIN KINASES
TW200736196A (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
BR0109161A (en) Beta-carbolines replaced with ikb-kinase inhibiting activity
PT1049703E (en) N-2- (5-BENZYLOXYCARBONYLAMINO-6-OXO-2- (4-FLUOROPHENYL) -1,6-DIHYDRO-1-PYRIMIDINYL) ACETOXYL-ASPARTIC ACID AS INHIBITOR OF THE INVENTION INTERLEUCINA-1BETA IN VIVO
RU94045149A (en) Agent for inhibition of pulmonary hypertension diseases
NO20055565L (en) Use of derivatives of 2,4-dihydro- [1,2,4] triazol-3-thione as inhibitors of the enzyme myeloperoxidase (MPO)
JO2216B1 (en) 5-chloro-3-(4 methanesulfonylphenyl)-6 methyl-(2.3) bipyridinly in pure crystalline form and process for synthesis
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
Michaelides et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors
ATE357453T1 (en) COMT INHIBITORS
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
BR0008437A (en) Steroid sulfatase inhibitors and methods for their manufacture and use
PT1268472E (en) 3-AMINOPIRAZOLIC INHIBITORS OF CYCLINE DEPENDENT KINASES
BR0200341A (en) Biphenylsulfonamides useful as matrix metalloprotease inhibitors
ATE389655T1 (en) PYRIMIDINE DERIVATIVES
Chen et al. Semi‐Synthesis and Biological Evaluation of 1, 2, 3‐Triazole‐Based Podophyllotoxin Congeners as Potent Antitumor Agents Inducing Apoptosis in HepG2 Cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application